FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2479891340> ?p ?o ?g. }

• W2479891340 abstract "In the United States, breast cancer affects 1 in 8 women during their lifetime. The National Cancer Institute estimated that this means 231,840 new breast cancer cases will arises in 2015, attributing to 40,290 mortalities. Survival of breast cancer and prognosis depends mainly on the type and aggressiveness of the cancer; invasive carcinomas contribute to the majority of cancer related deaths. As such, detection and early stage treatment of breast cancer is crucial to increasing prognosis and favorable outcome. Platinum based chemotherapeutics are widely accepted as a standard treatment for breast cancer. Current drugs on the market, including cisplatin and carboplatin, have been shown to effectively reduce tumor size and improve patient prognosis. However, many patients eventually relapse, developing new tumors that are chemo-resistant, along with exhibiting debilitating side effects, often leading to discontinuation of treatment. To combat this growing problem, we devised and synthesized a new analog of Carboplatin, entitled “Pt-Mal-LHRH”, to selectively target breast cancer cells overexpressing the LHRH receptor. Our initial results utilizing Pt-Mal-LHRH in-vitro showed a higher potency towards 4T1 (stage IV) breast cancer cells compared to those treated with Carboplatin. Cell viability was analyzed by an MTT assay, resulting in significant, (p>0.01), reduction in viable cancer cells treated with Pt-Mal-LHRH compared to those treated with Carboplatin. In addition, drug uptake was evaluated by ICP-MS after cells were treated with either Pt-Mal-LHRH or Carboplatin, displaying a 20-fold increase in 4T1 cellular uptake of Pt-Mal-LHRH compared to Carboplatin. We also found that Pt-Mal-LHRH selectively targets 4T1 breast cancer cells as there was a significant,(p>0.0001), decrease in 4T1 cell viability compared to normal mammary cells. In addition, Pt-Mal-LHRH showed a significant decrease in cell migration using an in-vitro scratch/cell migration assay. Subsequently, using an in-vivo mouse model, our findings showed a significant, (p>0.05), reduction in tumor volume in mice treated with Pt-Mal-LHRH (5 mg/kg/wk) through IP injection compared to those injected with Carboplatin. Furthermore, metastasis and tumor colonization in the lungs was significantly attenuated in Pt-Mal-LHRH treated mice compared to control and Carboplatin treated. Lastly, there was a slight decrease in lung weight and no difference in liver weight between treatment groups. Together, our data indicates that Pt-Mal-LHRH is potentially a more potent and selective chemotherapeutic agent than other platinum based drugs currently on the market, such as Carboplatin. Citation Format: Joseph D. Rollins, Lindsay Calderon, Margaret Ndinguri. Pt-Mal-LHRH, a newly synthesized compound attenuating breast cancer tumor growth and metastasis by targeting overexpression of the LHRH receptor. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-230." @default.
• W2479891340 created "2016-08-23" @default.
• W2479891340 creator A5018821685 @default.
• W2479891340 creator A5056928449 @default.
• W2479891340 creator A5057011555 @default.
• W2479891340 date "2016-07-15" @default.
• W2479891340 modified "2023-09-26" @default.
• W2479891340 title "Abstract LB-230: Pt-Mal-LHRH, a newly synthesized compound attenuating breast cancer tumor growth and metastasis by targeting overexpression of the LHRH receptor" @default.
• W2479891340 doi "https://doi.org/10.1158/1538-7445.am2016-lb-230" @default.
• W2479891340 hasPublicationYear "2016" @default.
• W2479891340 type Work @default.
• W2479891340 sameAs 2479891340 @default.
• W2479891340 citedByCount "0" @default.
• W2479891340 crossrefType "proceedings-article" @default.
• W2479891340 hasAuthorship W2479891340A5018821685 @default.
• W2479891340 hasAuthorship W2479891340A5056928449 @default.
• W2479891340 hasAuthorship W2479891340A5057011555 @default.
• W2479891340 hasConcept C121608353 @default.
• W2479891340 hasConcept C126322002 @default.
• W2479891340 hasConcept C143998085 @default.
• W2479891340 hasConcept C2776694085 @default.
• W2479891340 hasConcept C2778239845 @default.
• W2479891340 hasConcept C2779013556 @default.
• W2479891340 hasConcept C2781451048 @default.
• W2479891340 hasConcept C502942594 @default.
• W2479891340 hasConcept C530470458 @default.
• W2479891340 hasConcept C71924100 @default.
• W2479891340 hasConcept C96232424 @default.
• W2479891340 hasConceptScore W2479891340C121608353 @default.
• W2479891340 hasConceptScore W2479891340C126322002 @default.
• W2479891340 hasConceptScore W2479891340C143998085 @default.
• W2479891340 hasConceptScore W2479891340C2776694085 @default.
• W2479891340 hasConceptScore W2479891340C2778239845 @default.
• W2479891340 hasConceptScore W2479891340C2779013556 @default.
• W2479891340 hasConceptScore W2479891340C2781451048 @default.
• W2479891340 hasConceptScore W2479891340C502942594 @default.
• W2479891340 hasConceptScore W2479891340C530470458 @default.
• W2479891340 hasConceptScore W2479891340C71924100 @default.
• W2479891340 hasConceptScore W2479891340C96232424 @default.
• W2479891340 hasLocation W24798913401 @default.
• W2479891340 hasOpenAccess W2479891340 @default.
• W2479891340 hasPrimaryLocation W24798913401 @default.
• W2479891340 hasRelatedWork W1643378484 @default.
• W2479891340 hasRelatedWork W1679717407 @default.
• W2479891340 hasRelatedWork W2015302300 @default.
• W2479891340 hasRelatedWork W2024983017 @default.
• W2479891340 hasRelatedWork W2026009684 @default.
• W2479891340 hasRelatedWork W2027868367 @default.
• W2479891340 hasRelatedWork W2111042503 @default.
• W2479891340 hasRelatedWork W2314853851 @default.
• W2479891340 hasRelatedWork W2325583904 @default.
• W2479891340 hasRelatedWork W2372399482 @default.
• W2479891340 hasRelatedWork W2399926935 @default.
• W2479891340 hasRelatedWork W2403535695 @default.
• W2479891340 hasRelatedWork W2535172734 @default.
• W2479891340 hasRelatedWork W2548780836 @default.
• W2479891340 hasRelatedWork W2562360454 @default.
• W2479891340 hasRelatedWork W2566462879 @default.
• W2479891340 hasRelatedWork W2740174425 @default.
• W2479891340 hasRelatedWork W2912119489 @default.
• W2479891340 hasRelatedWork W3039669102 @default.
• W2479891340 hasRelatedWork W3182886812 @default.
• W2479891340 isParatext "false" @default.
• W2479891340 isRetracted "false" @default.
• W2479891340 magId "2479891340" @default.
• W2479891340 workType "article" @default.